S&P 500   3,728.51 (-1.65%)
DOW   29,915.18 (-1.32%)
QQQ   275.98 (-2.18%)
AAPL   143.69 (-1.65%)
MSFT   244.43 (-1.79%)
META   134.95 (-3.80%)
GOOGL   98.96 (-2.64%)
AMZN   118.11 (-2.46%)
TSLA   234.09 (-6.15%)
NVDA   126.60 (-3.85%)
NIO   15.74 (-5.92%)
BABA   83.69 (-0.50%)
AMD   64.89 (-4.43%)
T   15.77 (-1.99%)
MU   52.73 (-2.28%)
CGC   2.97 (-5.41%)
F   12.15 (-1.70%)
GE   66.57 (-1.44%)
DIS   99.00 (-2.41%)
AMC   7.10 (-9.32%)
PYPL   91.26 (-1.65%)
PFE   43.82 (-1.44%)
NFLX   228.68 (-5.01%)
S&P 500   3,728.51 (-1.65%)
DOW   29,915.18 (-1.32%)
QQQ   275.98 (-2.18%)
AAPL   143.69 (-1.65%)
MSFT   244.43 (-1.79%)
META   134.95 (-3.80%)
GOOGL   98.96 (-2.64%)
AMZN   118.11 (-2.46%)
TSLA   234.09 (-6.15%)
NVDA   126.60 (-3.85%)
NIO   15.74 (-5.92%)
BABA   83.69 (-0.50%)
AMD   64.89 (-4.43%)
T   15.77 (-1.99%)
MU   52.73 (-2.28%)
CGC   2.97 (-5.41%)
F   12.15 (-1.70%)
GE   66.57 (-1.44%)
DIS   99.00 (-2.41%)
AMC   7.10 (-9.32%)
PYPL   91.26 (-1.65%)
PFE   43.82 (-1.44%)
NFLX   228.68 (-5.01%)
S&P 500   3,728.51 (-1.65%)
DOW   29,915.18 (-1.32%)
QQQ   275.98 (-2.18%)
AAPL   143.69 (-1.65%)
MSFT   244.43 (-1.79%)
META   134.95 (-3.80%)
GOOGL   98.96 (-2.64%)
AMZN   118.11 (-2.46%)
TSLA   234.09 (-6.15%)
NVDA   126.60 (-3.85%)
NIO   15.74 (-5.92%)
BABA   83.69 (-0.50%)
AMD   64.89 (-4.43%)
T   15.77 (-1.99%)
MU   52.73 (-2.28%)
CGC   2.97 (-5.41%)
F   12.15 (-1.70%)
GE   66.57 (-1.44%)
DIS   99.00 (-2.41%)
AMC   7.10 (-9.32%)
PYPL   91.26 (-1.65%)
PFE   43.82 (-1.44%)
NFLX   228.68 (-5.01%)
S&P 500   3,728.51 (-1.65%)
DOW   29,915.18 (-1.32%)
QQQ   275.98 (-2.18%)
AAPL   143.69 (-1.65%)
MSFT   244.43 (-1.79%)
META   134.95 (-3.80%)
GOOGL   98.96 (-2.64%)
AMZN   118.11 (-2.46%)
TSLA   234.09 (-6.15%)
NVDA   126.60 (-3.85%)
NIO   15.74 (-5.92%)
BABA   83.69 (-0.50%)
AMD   64.89 (-4.43%)
T   15.77 (-1.99%)
MU   52.73 (-2.28%)
CGC   2.97 (-5.41%)
F   12.15 (-1.70%)
GE   66.57 (-1.44%)
DIS   99.00 (-2.41%)
AMC   7.10 (-9.32%)
PYPL   91.26 (-1.65%)
PFE   43.82 (-1.44%)
NFLX   228.68 (-5.01%)
NASDAQ:MGNX

MacroGenics - MGNX Stock Forecast, Price & News

$3.43
-0.28 (-7.55%)
(As of 10/5/2022 10:50 AM ET)
Add
Compare
Today's Range
$3.42
$3.68
50-Day Range
$3.01
$5.22
52-Week Range
$2.13
$22.68
Volume
3,966 shs
Average Volume
555,800 shs
Market Capitalization
$210.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
232.4% Upside
$12.33 Price Target
Short Interest
Bearish
8.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.24) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

217th out of 1,087 stocks

Pharmaceutical Preparations Industry

93rd out of 546 stocks

MGNX stock logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

Where Macrogenics Stands With Analysts
Macrogenics: Q2 Earnings Insights - Benzinga
MacroGenics (MGNX) Q2 2022 Earnings Call Transcript
MacroGenics: Q2 Earnings Snapshot - Greenwich Time
Analyst Ratings for Macrogenics
Analysts Cuts Price Target On MacroGenics - Read Why
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings
8/08/2022
Today
10/05/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
427
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+259.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-202,120,000.00
Net Margins
-326.76%
Pretax Margin
-326.76%

Debt

Sales & Book Value

Annual Sales
$77.45 million
Book Value
$3.91 per share

Miscellaneous

Free Float
56,604,000
Market Cap
$210.81 million
Optionable
Optionable
Beta
1.92

Key Executives

  • Dr. Scott Koenig M.D. (Age 70)
    Ph.D., Pres, CEO & Director
    Comp: $954.14k
  • Mr. James  KarrelsMr. James Karrels (Age 55)
    Sr. VP, CFO & Corp. Sec.
    Comp: $577.9k
  • Mr. Eric Blasius Risser (Age 49)
    Chief Operating Officer
    Comp: $571.98k
  • Dr. Ezio Bonvini (Age 68)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 55)
    Sr. VP of Technical Operations
    Comp: $550.97k
  • Dr. Christopher Shayne James M.D.
    VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters (Age 50)
    Sr. VP & Gen. Counsel
  • Dr. Stephen L. Eck M.D. (Age 67)
    Ph.D., Sr. VP of Clinical Devel. & Chief Medical Officer
  • Ms. Lynn Cilinski (Age 64)
    VP, Controller & Treasurer













MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2022?

8 analysts have issued 1-year price targets for MacroGenics' stock. Their MGNX share price forecasts range from $4.00 to $30.00. On average, they predict the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 232.4% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2022?

MacroGenics' stock was trading at $16.05 at the beginning of the year. Since then, MGNX shares have decreased by 76.9% and is now trading at $3.71.
View the best growth stocks for 2022 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.30. The biopharmaceutical company earned $26.01 million during the quarter, compared to analysts' expectations of $14.59 million. MacroGenics had a negative trailing twelve-month return on equity of 102.68% and a negative net margin of 326.76%.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $3.71.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $228.02 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.56) on an earnings per share basis.

How many employees does MacroGenics have?

The company employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.